BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
- Conditions
- Pancreatic Neuroendocrine Tumors (pNET)
- Interventions
- Drug: BEZ235 (Stage 1)
- Registration Number
- NCT01658436
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.
Study design: This was a Phase II, two-stage, multicenter study, where Stage 1 was a single arm, open label design and Stage 2 was planned to be a randomized, double-blind study.
However, at the end of Stage 1, the futility was met and hence the Stage 2 was not initiated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
- Unresectable or metastatic, histologically confirmed low or intermediate grade pancreatic neuroendocrine tumor with radiological evidence of disease progression since last treatment
- Refractory disease to treatment with mTOR inhibitor
- Measurable disease per RECIST Version 1.1 using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)
- Prior or concurrent therapy with SSA is permitted; a stable dose at least 2 months prior to study start and must continue on the stable dose while receiving study treatment; SSA is not considered as a systemic treatment.
- WHO PS ≤ 1
- Adequate bone marrow function or organ function
- Previous treatment with any PI3K or AKT inhibitor
- Discontinuation prior mTOR inhibitor therapy due to toxicity
- Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma
- Radiotherapy, or major surgery within 4 weeks prior to study treatment start
- Hepatic artery embolization or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of study treatment start.
- More than 3 prior systemic treatment regimens (including cytotoxic chemotherapy, targeted therapy, immunotherapy)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description BEZ235 300 mg/400 mg bid (Stage 1) BEZ235 (Stage 1) Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
- Primary Outcome Measures
Name Time Method Stage 1 - Progression Free Survival (PFS) Rate Analysis at 16 Weeks as Per Local Radiology Review 16 weeks after the first BEZ235 administration. PFS rate at 16 weeks was defined as a binary variable. Patients were considered as 'progression free' after 16 weeks if they had an overall lesion response of complete response (CR) partial response ('PR) or stable disease (SD)' and "progressed" if they had an overall lesion response of 'Progressive disease (PD) at the scan which occurred on day 105 after start of treatment, or later. Patients whose 16 weeks tumor assessment was unknown, missing or outside the window was not considered as 'progression free' and was considered a "failure" and counted only in the denominator for the estimation of the 16 week progression free rate.
- Secondary Outcome Measures
Name Time Method Stage 1- Overall Response Rate (ORR) Baseline, every 8 weeks up to 31 months Overall Response rate was defined as the proportion of patients with a best overall response of complete response or partial response, based on investigator's assessment as per RECIST criteria version 1.1. Based on futility analysis conducted at the end of stage 1, stage 2 was not initiated.
Stage 1 - Disease Control Rate Baseline, every 8 weeks up to 31 months Disease control rate was defined as the proportion of patients with a best overall response of Complete Response, Partial response, or Stable disease, based on the investigator's assessment per RECIST version 1.1. Based on futility analysis conducted at the end of stage 1, stage 2 was not initiated.
Trial Locations
- Locations (5)
Indiana University SC
🇺🇸Indianapolis, Indiana, United States
Dana Farber Cancer Institute GastrointestionalCancer Clinic
🇺🇸Boston, Massachusetts, United States
Montefiore Medical Center SC-2
🇺🇸Bronx, New York, United States
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC
🇺🇸Columbus, Ohio, United States
Novartis Investigative Site
🇬🇧Manchester, United Kingdom